Future research needs to look at the role of antithrombotic therapy following percutaneous left atrial appendage closure.
Patients with CKD stage 3 or 4 and atrial fibrillation treated with apixaban vs warfarin have a 36% decreased risk of stroke or venous thromboembolism, a meta-analysis found.
According to the findings of a recent study, attorney advertisements appear to influence patients’ decisions on modifying or discontinuing their direct oral anticoagulant (DOAC) medication prior to seeking medical advice.
For morbidly obese patients with atrial fibrillation (AF), those undergoing preablation bariatric surgery have reduced rates of recurrence.
In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations.
Among patients who presented to the emergency department with recent-onset symptomatic atrial fibrillation, a wait-and-see strategy was noninferior to early cardioversion in obtaining sinus rhythm at 4 weeks after the index visit.
The FDA has cleared KardiaMobile (AliveCor), a personal ECG device, for use in detecting bradycardia and tachycardia.
A neural network can accurately identify the manufacturer and model group of a cardiac rhythm device from a chest radiograph.
Attending to modifiable risk factors is an important treatment target in patients with atrial fibrillation treated with anticoagulants to reduce thromboembolic and bleeding events.
Women have higher rates of complications and hospital readmission following atrial fibrillation ablation independent of age, comorbidities, and hospital factors.